Valuation: Erasca, Inc.

Market Cap 5.86B 5.13B 4.73B 4.39B 8.34B 559B 8.45B 56.6B 22.03B 274B 22.01B 21.53B 952B P/E 2026 *
-19.6x
P/E 2027 * -33.4x
Enterprise Value 5.19B 4.55B 4.19B 3.89B 7.38B 495B 7.48B 50.12B 19.5B 243B 19.49B 19.06B 843B EV / Sales 2026 *
-
EV / Sales 2027 * 10,283x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day-0.42%
1 week+1.20%
Current month+1.20%
1 month+44.06%
3 months+8.68%
6 months+258.61%
Current year+398.39%
1 week 17.24
Extreme 17.24
19
1 month 12.26
Extreme 12.26
19
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer - 25/05/2022
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%+1.20%+1,205.63%+576.64% 5.86B
-0.62%+5.83%+3.51%+10.02% 50.25B
-0.31%+0.92%+415.41%+616.18% 40.39B
+0.85%+7.60%+27.98%-4.10% 34.38B
-0.87%+8.22%+27.97%+62.70% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+1.86%+1.83% - - 16.64B
-2.89%+4.62%+73.73%+135.23% 16.14B
+0.64%+0.82%+14.66%+21.82% 13.71B
+2.75%+7.60%+104.20%+104.20% 13.75B
Average +0.21%+3.58%+208.69%+172.95% 25.18B
Weighted average by Cap. +0.05%+4.07%+122.89%+151.33%

Financials

2026 *2027 *
Net sales - 500K 438K 403K 374K 711K 47.69M 721K 4.83M 1.88M 23.41M 1.88M 1.84M 81.17M
Net income -299M -261M -241M -224M -425M -28.48B -430M -2.88B -1.12B -13.98B -1.12B -1.1B -48.47B -189M -166M -153M -142M -269M -18.06B -273M -1.83B -712M -8.87B -711M -695M -30.74B
Net Debt -672M -588M -542M -503M -955M -64.08B -968M -6.49B -2.52B -31.45B -2.52B -2.47B -109B -721M -631M -581M -540M -1.02B -68.74B -1.04B -6.96B -2.71B -33.74B -2.71B -2.65B -117B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
07/07/26 $18.51 -1.80% 1,626,111
06/07/26 $18.85 +2.06% 4,539,684
02/07/26 $18.47 +3.07% 4,096,130
01/07/26 $17.92 -2.18% 3,890,130
30/06/26 $18.32 +0.16% 5,407,603
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.85USD
Average target price
21.00USD
Spread / Average Target
+11.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock